Renowned Review, The Performing Artist Issue 2, and fine-art book Life of the Day mark three new KL Publishing Group releases under Executive Editor Kaylene Peoples. The post KL Publishing Group Announces Three New Releases Celebrating Fashion, Entertainment, and Fine Art first appeared on
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared...
JelluTide Gummies, its listed formulation categories, ingredient information, product details, and responsible supplement labeling. JelluTide Gummies, its listed formulation categories, ingredient information, product details, and responsible supplement labeling.
Quanta presents positive clinical combination data in KRAS G12D-mutant CRC at ESMO and highlights pan-KRAS progress with advancement of QTX6255
CAMBRIDGE, Mass., Oct. 24, 2026 -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced updated safety and efficacy data for zolucatetide, the first and only direct inhibitor of the β-catenin:TCF interaction, in patients with desmoid tumors. The data were presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain. The updated results, based on a June 22, 2026, data cutoff, include data from both the dose escalation and dose optimization portions of the ongoing Phase 1/2 trial and reinforce the strong efficacy and favorable safety and tolerability profile observed with zolucatetide. Among response-evaluable patients who began treatment at a starting dose of ≥450 mg, zolucatetide demonstrated an objective response rate (ORR) of 72.2% (13/18) in a 32-week landmark analysis. A disease control rate (DCR) of 100% was observed across all 46 response-evaluable patients who received a starting dose of ≥450 mg, with no disease progression. Data from a three-arm randomized dose optimization trial supported selection of a 450 mg weekly induction regimen administered for four cycles, followed by 300 mg every two weeks for long-term maintenance. Following productive end-of-Phase 2 discussions, Parabilis has reached alignment with the U.S. Food and Drug Administration (FDA) on the selected dose and regimen, on the use of a placebo-controlled study design, and on progression-free survival (PFS) as the primary endpoint for registrational development. Parabilis plans to initiate the randomized, double-blind PEDESTAL Phase 3 trial (Phase 3 Evaluation of DESmoid Tumor Activity with zoLucatetide) in the first half of 2027, with topline results anticipated in 2029. “Desmoid tumors are chronic and life-altering for patients, often affecting people at a young age, and patients need treatments that can deliver rapid, deep and durable tumor responses with a tolerability profile suited for long-term treatment,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO and President of Parabilis Medicines. “We designed zolucatetide to directly inhibit β-catenin:TCF, a historically undruggable target at the heart of the biology driving these tumors. The depth and consistency of responses we are seeing, together with the favorable safety and tolerability profile observed to date, reinforce our conviction that zolucatetide has the potential to deliver a truly differentiated medicine and meaningfully expand the number of patients who can benefit from treatment. We are very pleased with the clarity of the FDA’s feedback on our registrational development strategy, and with our Phase 3 regimen selected, we are moving with urgency to bring this medicine to patients.” Updated Phase 1/2 Results As of the June 22, 2026, data cutoff, 76 patients with desmoid tumors had been enrolled and treated across all dose levels in the dose escalation and dose optimization portions of the trial. Median age was 37 years (range 19–80), and 69.7% of patients were female. The population included both patients who had previously been treated with and failed gamma-secretase inhibitors (GSIs) and patients naive to GSIs.
MEDIA, PA / October 24, 2026 / McIntosh Lawyers, PC is strengthening its approach to complex financial issues arising during divorce, with a continued focus on helping clients understand and address property division, asset valuation, marital debts, business interests, retirement accounts, and other financial considerations that can affect divorce proceedings. Based in Media, Pennsylvania, McIntosh
INTO BLACK, a Texas-made WWII thriller, screens November 7 at the inaugural Addison Full Circle Film Festival. The Addison Full Circle Film Festival Fans decide what gets made next. November 7 feature and filmmaker Q&A highlight the inaugural festival supported by title sponsor I Am A Fan That’s exactly what a festival like Addison Full Circle makes possible - putting independent storytellers in the same room as the
TORONTO, ON / October 24, 2026 / Marblebee Ltd., a specialist in custom marble craftsmanship and natural stone architectural solutions, is strengthening its position in luxury interior and exterior design by offering personalized stone creations that combine timeless artistry with contemporary aesthetics
New research spans world models, vision-language-action models, reinforcement learning, predictive memory and real-world robot benchmarks New research spans world models, vision-language-action models, reinforcement learning, predictive memory and real-world robot benchmarks
OKLAHOMA CITY, OK / October 24, 2026 / The Urbanic Law Firm is strengthening its criminal defense representation across Oklahoma, providing focused legal support to individuals facing criminal allegations in state, federal, and municipal cases. Based in Oklahoma City, the firm represents clients throughout the state in matters involving DUI and DWI, domestic violence, drug offenses, sex crimes, fire
BANGKOK, THAILAND / October 24, 2026 / Makers of the capacitors, magnets and battery materials inside AI servers and electric vehicles (EVs) are lining up to invest in Thailand. Since 2023, they have filed 35 advanced materials projects worth about $690 million (23.5 billion baht) with the Thailand Board
SINGAPORE, Oct. 24, 2026 -- The upgraded JST Buyback and Burn program features the following highlights: · $50M Treasury Reserve Cushion: Establishes a safety buffer for sustainable ecosystem operations. · Expanded Funding Sources: Integrates GasFree revenue alongside JustLend and USDD to cover 100% of JUST core products. · ~$20.34M Capital Injection: Unlocks legacy surplus funds to be released in phases for future buybacks. · JUST DAO Execution: Complete on-chain execution with full transparency and open-source verification.